Laddar populära aktier...
Redeye comments on Oncopeptides Q3 report 2024. Revenues in Q3 increased slightly compared to Q2, but product sales declined.
Redeye comments on Oncopeptides’ licensing deal for Pepaxti in South Korea.
Redeye provides a brief comment on the selection of a new drug candidate.
Redeye comments on Oncopeptides' Q1 report, which had few surprises in terms of financials.
Redeye comments on the outcome of Oncopeptide's rights issue.
Redeye comments on the decision of NICE not to recommend Pepaxti in the UK, which is not unexpected.
Redeye initiates coverage of Oncopeptides, a commercial-stage biotech company focusing on multiple myeloma.
